Comparison oftecar therapy versus phonophoresis on improvement of symptoms of patients with mild and moderate carpal tunnel syndrome

Comparative effect of tecar therapy versus phonophoresis on improvement of symptoms, function and electrodiagnostic and sonographic findings in patients with mild to moderate carpal tunnel syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220305054198N1

Enrollment

Registered

2022-04-03

Start date

2022-04-04

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal tunnel syndrome. Carpal tunnel syndrome

Interventions

Intervention 1: Intervention group 1: Patients in this group will receive standard treatments. In addition, patients will receive Tecar therapy(TECAR WINBACK made in France). In this way, the patient

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of mild to moderate carpal tunnel syndrome by nerve and muscle tape Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Rheumatoid arthritis, diabetes, hypothyroidism, peripheral vascular disease, active cancer, cervical radiculopathy and polyneuropathy Pregnancy Having a Heart Pacemaker Having a history of corticosteroid injection in the carpal tunnel area in the last quarter Having a history of carpal tunnel syndrome surgery

Design outcomes

Primary

Measure	Time frame
Severity of symptoms. Timepoint: Before, immediately, one month and three months after the intervention. Method of measurement: Boston Questionnaire.;Function score. Timepoint: Before, immediately, one month and three months after the intervention. Method of measurement: Boston Questionnaire.;Cross-sectional area (CSA) of the median nerve. Timepoint: Before and three months after the intervention. Method of measurement: Sonography.;Pain. Timepoint: Before, immediately, one month and three months after the intervention. Method of measurement: Visual Analogue Scale.;Nerve Conduction Velocity (NCV) across wrist. Timepoint: Before and three months after the intervention. Method of measurement: Nerve and muscle strip.;Sensory nerve action potential (SNAP) latency from median nerves. Timepoint: Before and three months after the intervention. Method of measurement: Nerve and muscle strip.;Compound Muscle Action Potential (CMAP) Amplitude from median nerves. Timepoint: Before and three months after the intervention. Method of measurement: Nerve and muscle strip.	—

Measure

Time frame

Severity of symptoms. Timepoint: Before, immediately, one month and three months after the intervention. Method of measurement: Boston Questionnaire.;Function score. Timepoint: Before, immediately, one month and three months after the intervention. Method of measurement: Boston Questionnaire.;Cross-sectional area (CSA) of the median nerve. Timepoint: Before and three months after the intervention. Method of measurement: Sonography.;Pain. Timepoint: Before, immediately, one month and three months after the intervention. Method of measurement: Visual Analogue Scale.;Nerve Conduction Velocity (NCV) across wrist. Timepoint: Before and three months after the intervention. Method of measurement: Nerve and muscle strip.;Sensory nerve action potential (SNAP) latency from median nerves. Timepoint: Before and three months after the intervention. Method of measurement: Nerve and muscle strip.;Compound Muscle Action Potential (CMAP) Amplitude from median nerves. Timepoint: Before and three months after the intervention. Method of measurement: Nerve and muscle strip.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeid Khosrawi

Esfahan University of Medical Sciences

khosrawi@med.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026